AC
OPTN

Armistice Capital’s OptiNose OPTN Stock Holding History

Armistice Capital’s Portfolio OPTN Stock Details OPTN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-133,099
Closed -$3.69M – 245
2022
Q4 		$3.69M Buy
+133,099
New +$5.05M 0.06% 106

Other funds holding OPTN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $10.8M AUM 61.97% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Armistice Capital's OPTN Position: Q1 2023 in Review

Armistice Capital sold out of OptiNose (OPTN) in Q1 2023, closing a stake of 133,099 shares — an estimated $3.69M sold.

Armistice Capital first reported a position in OPTN in Q4 2022 and held it in 1 quarter. The position peaked at $3.69M in Q4 2022. 62 funds tracked by Wall St. Rank hold OPTN as of Q1 2023.

  • Armistice Capital reported no remaining OptiNose position as of Q1 2023 after selling out during the quarter.
  • Armistice Capital sold 133,099 OptiNose shares in Q1 2023, an estimated $3.69M.
  • Armistice Capital first reported a position in OptiNose in Q4 2022 and held it in 1 quarter.
  • Armistice Capital's OptiNose position peaked at $3.69M in Q4 2022.
  • 62 funds tracked by Wall St. Rank held OptiNose as of Q1 2023.

Based on Armistice Capital's 13F filing for Q1 2023, filed 15 May 2023.